Articles related to CHEMOTHERAPY

A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.

In a retrospective VA cohort of 669 mCRPC patients who did not progress on initial docetaxel, rechallenge with docetaxel was associated with improved overall survival compared with cabazitaxel after inverse probability of treatment weighting, though short follow-up and inherent selection pressures limit interpretation.

Tafasitamab plus lenalidomide added to R-CHOP reduced the risk of progression or death by 25% compared with R-CHOP alone in previously untreated high-risk DLBCL and HGBL in a 899-patient phase 3 trial, with overall survival data not yet mature.

A phase 3 randomized trial of 449 children with intracranial ependymoma found no significant event-free or overall survival benefit from adding maintenance chemotherapy after radiation, while molecular markers — particularly 1q gain and 6q loss — identified a high-risk posterior fossa subgroup with substantially worse outcomes.

DAGO2 produced 3-year overall survival of 52% versus 35% with CPX-351 in older patients with non-adverse-risk AML in a 439-patient randomized comparison.

“The SunRISe-2 trial was stopped in advance for futility based on week-18 overall response rate assessment and the totality of the efficacy data. However, the CR rates in both arms are compelling.” — Andrea Necchi, MD, ASCO GU Symposium 2026